◆ TICKERBASE · GLOBAL STOCK FINANCIAL DATA LIBRARY

Arrowhead Pharmaceuticals Inc (ARWR)

Name: Arrowhead Pharmaceuticals Inc（ARWR）— 財務諸表の推移
Creator: TickerBase
License: https://creativecommons.org/licenses/by/4.0/

公式財務諸表に基づく売上高、利益、キャッシュフローの推移。

HEALTHCARE · ウォール街（米国） · 最終更新: 2026-08-16

Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. Its pipeline includes Plozasiran to reduce production of apolipoprotein C-III in Phase 3 studies; Zodasiran to reduce production of angiopoietin-like protein 3 in Phase 3 clinical trials; ARO-DIMER-PA, a dual functional RNAi molecule in a Phase 1/2a clinical trials; and ARO-PNPLA3, an investigational RNAi therapeutic in Phase 1 clinical trials.

主要指標

時価総額: $12 billion
売上高（2025-09-30 期末の会計年度）: $829M
当期純利益: ($2M)
売上総利益率: 100.0%
純利益率: -0.2%

インタラクティブチャートと全財務諸表を見る → バリュエーションモデル（DCF）→

年次損益計算書

損益計算書	TTM → 2026-06-30	2025-09-30	2024-09-30	2023-09-30	2022-09-30	2021-09-30	2020-09-30	2019-09-30	2018-09-30	2017-09-30	2016-09-30	2015-09-30	2014-09-30	2013-09-30	2012-09-30	2011-09-30	2010-09-30	2009-09-30	2008-09-30	2007-09-30	2006-09-30
売上高合計	$669M	$829M	$4M	$241M	$243M	$138M	$88M	$169M	$16M	$31M	$0M	$0M	$0M	$0M	$0M	$0M	$1M	$4M	$1M	$1M	$1M
売上総利益	—	$829M	($15M)	$228M	$243M	$138M	$88M	$169M	$16M	$31M	$0M	$0M	($4M)	($3M)	($2M)	$0M	($4M)	($5M)	($14M)	($11M)	($7M)
売上総利益率 %	—	100.0%	-423.7%	94.8%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	-2076.2%	-993.2%	-1090.8%	9.5%	-698.7%	-139.9%	-1039.8%	-874.8%	-1135.7%
営業利益（EBIT）	($226M)	$98M	($601M)	($205M)	($179M)	($149M)	($93M)	$61M	($56M)	($37M)	($82M)	($96M)	($53M)	($25M)	($21M)	($10M)	($9M)	($20M)	($35M)	($38M)	($20M)
営業利益率 %	-33.8%	11.9%	-16927.1%	-85.2%	-73.4%	-107.8%	-105.9%	36.2%	-346.5%	-117.8%	-51627.1%	-25124.1%	-30443.6%	-8471.3%	-14358.6%	-3319.5%	-1419.5%	-520.5%	-2685.9%	-3141.4%	-3439.9%
当期純利益	($320M)	($2M)	($599M)	($205M)	($176M)	($141M)	($85M)	$68M	($54M)	($34M)	($82M)	($92M)	($59M)	($31M)	($21M)	($3M)	($6M)	($19M)	($27M)	($30M)	($19M)
純利益率 %	-47.8%	-0.2%	-16882.4%	-85.3%	-72.6%	-101.8%	-96.1%	40.3%	-337.3%	-109.5%	-51614.6%	-24068.3%	-33503.0%	-10729.2%	-14383.6%	-1056.6%	-931.2%	-513.8%	-2078.7%	-2477.7%	-3190.3%
EBITDA	—	$165M	($562M)	($176M)	($168M)	($133M)	($87M)	$66M	($51M)	($32M)	($76M)	($94M)	($50M)	($22M)	($19M)	($10M)	($10M)	($19M)	($34M)	($37M)	($20M)
1株当たり利益（EPS）	$-2.25	$-0.01	$-5.00	$-1.92	$-1.67	$-1.36	$-0.84	$0.69	$-0.65	$-0.47	$-1.34	$-1.60	$-1.25	$-1.30	$-1.90	$-0.44	$-0.90	$-4.27	$-6.91	$-8.35	$-5.95
発行済株式数（百万株）	—	134M	120M	107M	105M	104M	101M	99M	84M	74M	61M	57M	47M	24M	11M	7M	6M	5M	4M	4M	3M

出典: 企業の公開資料（SEC）。数値をご利用の前に SEC EDGAR でご確認ください。

貸借対照表、キャッシュフロー計算書、四半期データおよび全財務比率は ARWR のインタラクティブ・ビューアーでご覧いただけます。 /companies/us/ARWR

類似企業

本サイトの情報は教育および情報提供のみを目的としており、投資助言ではありません。目標株価や投資判断は掲載していません。

English version →全銘柄

About TickerBase · Data methodology & sources · Privacy · Terms

TickerBase is provided for educational and informational purposes only. It does not constitute financial, investment, tax, or legal advice, or a recommendation to buy, sell, or hold any security. No price targets are published; any per-share value shown in the valuation workbench is generated entirely from reader-supplied assumptions and is not the publisher's view of fair value. Past performance does not predict future results. Figures are approximate and drawn from public filings; one-time items are noted where identified. Do your own research and consult a licensed professional before making any investment decision. The author may or may not hold positions in the securities discussed.